CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 136 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,950,615 | +52.3% | 2,075,556 | +11.9% | 0.00% | +100.0% |
| Q2 2023 | $20,317,403 | +157.5% | 1,855,470 | +105.0% | 0.00% | +100.0% |
| Q1 2023 | $7,891,239 | +159254.6% | 904,958 | +14.6% | 0.00% | 0.0% |
| Q4 2022 | $4,952 | -99.8% | 789,914 | +0.6% | 0.00% | – |
| Q3 2022 | $2,747,000 | +30.7% | 784,965 | +10.2% | 0.00% | – |
| Q2 2022 | $2,102,000 | -48.7% | 712,578 | -45.9% | 0.00% | -100.0% |
| Q1 2022 | $4,095,000 | +5.2% | 1,316,948 | +14.4% | 0.00% | – |
| Q4 2021 | $3,891,000 | -3.7% | 1,151,205 | +4.0% | 0.00% | -100.0% |
| Q3 2021 | $4,040,000 | -19.1% | 1,107,091 | -3.4% | 0.00% | 0.0% |
| Q2 2021 | $4,994,000 | -4.9% | 1,145,605 | -1.0% | 0.00% | 0.0% |
| Q1 2021 | $5,252,000 | -12.0% | 1,156,974 | +11.3% | 0.00% | 0.0% |
| Q4 2020 | $5,967,000 | -18.9% | 1,039,565 | +2.2% | 0.00% | 0.0% |
| Q3 2020 | $7,361,000 | +99.8% | 1,016,750 | -3.7% | 0.00% | 0.0% |
| Q2 2020 | $3,685,000 | +129.0% | 1,056,003 | -2.9% | 0.00% | – |
| Q1 2020 | $1,609,000 | -60.1% | 1,087,183 | -47.1% | 0.00% | – |
| Q4 2019 | $4,028,000 | -15.7% | 2,055,840 | +120.2% | 0.00% | -100.0% |
| Q3 2019 | $4,779,000 | -24.2% | 933,604 | +6.0% | 0.00% | -50.0% |
| Q2 2019 | $6,305,000 | -38.8% | 880,713 | +13.5% | 0.00% | -33.3% |
| Q1 2019 | $10,305,000 | +4.7% | 776,080 | -38.0% | 0.00% | +50.0% |
| Q4 2018 | $9,846,000 | +49.8% | 1,251,254 | +110.9% | 0.00% | 0.0% |
| Q3 2018 | $6,573,000 | -12.7% | 593,290 | +5.7% | 0.00% | 0.0% |
| Q2 2018 | $7,529,000 | +52.1% | 561,063 | +47.2% | 0.00% | 0.0% |
| Q1 2018 | $4,949,000 | +92.0% | 381,059 | +36.0% | 0.00% | +100.0% |
| Q4 2017 | $2,578,000 | +14.2% | 280,263 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,258,000 | +136.2% | 280,263 | +68.7% | 0.00% | – |
| Q2 2017 | $956,000 | +32.0% | 166,121 | -1.4% | 0.00% | – |
| Q1 2017 | $724,000 | +325.9% | 168,528 | +71.4% | 0.00% | – |
| Q4 2016 | $170,000 | -10.5% | 98,296 | 0.0% | 0.00% | – |
| Q3 2016 | $190,000 | +11.1% | 98,296 | 0.0% | 0.00% | – |
| Q2 2016 | $171,000 | +29.5% | 98,296 | 0.0% | 0.00% | – |
| Q1 2016 | $132,000 | -20.5% | 98,296 | 0.0% | 0.00% | – |
| Q4 2015 | $166,000 | 0.0% | 98,296 | +14.6% | 0.00% | – |
| Q3 2015 | $166,000 | +26.7% | 85,796 | +75.0% | 0.00% | – |
| Q2 2015 | $131,000 | -61.4% | 49,022 | 0.0% | 0.00% | – |
| Q1 2015 | $339,000 | +2.4% | 49,022 | +45.5% | 0.00% | – |
| Q4 2014 | $331,000 | – | 33,696 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |